Low Dose Weekly Docetaxel Versus Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Docetaxel and pemetrexed have been validated for previously treated advanced non-small cell
lung cancer (NSCLC); however, tolerability is a concern with the docetaxel (tri-weekly 75
mg/m2 schedule). The investigators conducted this study to compare the efficacy and toxicity
of weekly low-dose docetaxel versus tri-weekly pemetrexed for previously treated advanced
NSCLC.